Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF SURGERY
Volume 105, Issue 8, Pages 946-958
Publisher
Wiley
Online
2018-04-30
DOI
10.1002/bjs.10870
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
- (2017) Marianne Sinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial
- (2017) Knut Jørgen Labori et al. BMC Surgery
- Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact
- (2016) Yoshiaki Murakami et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma
- (2016) B. Ielpo et al. EJSO
- A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458)
- (2016) Walid L. Shaib et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting
- (2016) Tsutomu Fujii et al. JOURNAL OF GASTROENTEROLOGY
- Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality
- (2016) Jason W. Denbo et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement
- (2016) Seiko Hirono et al. PANCREAS
- Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors
- (2016) Toshihiko Masui et al. SURGERY TODAY
- Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
- (2016) Eva Versteijne et al. Trials
- Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer
- (2016) Matthew H. G. Katz et al. JAMA Surgery
- The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis
- (2016) Maikel J. Bakens et al. Cancer Medicine
- The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience
- (2015) Shalini Moningi et al. ANNALS OF SURGICAL ONCOLOGY
- Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer
- (2015) Omar M. Rashid et al. ANNALS OF SURGICAL ONCOLOGY
- Meta-analysis of radical resection rates and margin assessment in pancreatic cancer
- (2015) M. D. Chandrasegaram et al. BRITISH JOURNAL OF SURGERY
- Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets
- (2015) Riccardo Casadei et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Importance of resectability status in neoadjuvant treatment for pancreatic cancer
- (2015) Masayuki Sho et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment
- (2015) Tsutomu Fujii et al. MEDICINE
- Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival
- (2014) J. Bart Rose et al. ANNALS OF SURGICAL ONCOLOGY
- Neoadjuvant Therapy is Associated with a Reduced Lymph Node Ratio in Patients with Potentially Resectable Pancreatic Cancer
- (2014) Christina L. Roland et al. ANNALS OF SURGICAL ONCOLOGY
- Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma
- (2014) Brian A. Boone et al. ANNALS OF SURGICAL ONCOLOGY
- Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749)
- (2014) Michael Tachezy et al. BMC CANCER
- Impact of centralization of pancreatic cancer surgery on resection rates and survival
- (2014) G. A. Gooiker et al. BRITISH JOURNAL OF SURGERY
- Validation of Group B Borderline Resectable Pancreatic Cancer: Retrospective Analysis
- (2014) Tak Geun Oh et al. Gut and Liver
- Phase 2 Trial of Induction Gemcitabine, Oxaliplatin, and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer
- (2014) Nestor F. Esnaola et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?
- (2014) Amanda B. Cooper et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
- (2014) Henriette Golcher et al. STRAHLENTHERAPIE UND ONKOLOGIE
- A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
- (2013) Eileen M. OʼReilly et al. ANNALS OF SURGERY
- Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design
- (2013) Matthew H. G. Katz et al. ANNALS OF SURGICAL ONCOLOGY
- A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer
- (2013) Edward J. Kim et al. CANCER
- Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated
- (2013) Michael D. Chuong et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival
- (2013) Ching-Wei D. Tzeng et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Clinical features and treatment outcome of borderline resectable pancreatic head/body cancer: a multi-institutional survey by the Japanese Society of Pancreatic Surgery
- (2013) Hiroyuki Kato et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Does pre‐operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post‐operative morbidity? A case‐matched analysis
- (2013) Raphael L.C. Araujo et al. HPB
- Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
- (2013) Ching-Wei D. Tzeng et al. HPB
- Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
- (2012) Katia T. Papalezova et al. JOURNAL OF SURGICAL ONCOLOGY
- Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
- (2011) Stefan Heinrich et al. BMC CANCER
- Surgery for Pancreatic Carcinoma: State of the Art
- (2011) Shailesh V. Shrikhande et al. Indian Journal of Surgery
- Phase II Trial of Full-Dose Gemcitabine and Bevacizumab in Combination With Attenuated Three-Dimensional Conformal Radiotherapy in Patients With Localized Pancreatic Cancer
- (2011) William Small et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer
- (2011) Jerome Martin Laurence et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Neoadjuvant GTX Chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer
- (2011) Manish Patel et al. JOURNAL OF SURGICAL ONCOLOGY
- Preoperative chemoradiation followed by surgical resection for resectable pancreatic cancer: A review of current results
- (2011) Terence C. Chua et al. SURGICAL ONCOLOGY-OXFORD
- Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response
- (2010) O. Turrini et al. EJSO
- Clinical presentation and waiting time targets do not affect prognosis in patients with pancreatic cancer
- (2010) Dimitri A. Raptis et al. SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND
- Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma
- (2010) Philip Bao et al. HPB
- Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival
- (2010) Louise Barbier et al. HPB
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
- (2010) Sonja Gillen et al. PLOS MEDICINE
- Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review
- (2009) R. Le Scodan et al. ANNALS OF ONCOLOGY
- Feasibility and Efficacy of Combination Therapy With Preoperative Full-Dose Gemcitabine, Concurrent Three-Dimensional Conformal Radiation, Surgery, and Postoperative Liver Perfusion Chemotherapy for T3-Pancreatic Cancer
- (2009) Hiroaki Ohigashi et al. ANNALS OF SURGERY
- Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement
- (2009) Ross A. Abrams et al. ANNALS OF SURGICAL ONCOLOGY
- Neoadjuvant Chemoradiation in Patients With Potentially Resectable Pancreatic Cancer
- (2009) Soichiro Takai et al. PANCREAS
- Neoadjuvant Radiation Is Associated With Improved Survival in Patients With Resectable Pancreatic Cancer: An Analysis of Data From the Surveillance, Epidemiology, and End Results (SEER) Registry
- (2008) Alexander M. Stessin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Stefan Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Douglas B. Evans et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More